Guggenheim lowered the firm’s price target on Nautilus Biotechnology (NAUT) to $2.50 from $4 and keeps a Buy rating on the shares. A key area of focus was on the commercial launch timeline, which was pushed out a year to the end of 2026 from a prior view of the end of 2025, the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT: